Trending...
- Suburban Orthopaedics Expands Spine Team with Board-Certified Surgeon Joseph Brindise, DO
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- Digi 995: Warbot Run Officially Launches on the Apple App Store
WESTON, Fla., May 28, 2024 ~ Cantex Pharmaceuticals, Inc. has recently announced that their drug, azeliragon, will be featured in four abstracts at the 2024 ASCO Annual Meeting in Chicago. The company, which focuses on developing transformative therapies for cancer and other life-threatening medical conditions, is excited to showcase the progress of their clinical investigations at leading cancer centers.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Kanoa Debuts Gluten-Free Filled Cereals, Delivering Bold Flavor & Better Nutrition for Anytime Snac
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
Filed Under: Business
0 Comments
Latest on illi News
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
- STLE Launches Travel Grants Program to Support Tribology and Lubrication Engineering Professionals
- Digi 995: Void Run Pushes the Digiverse Into Its Darkest, Fastest Chapter Yet
- Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
- Bent Danholm Joins The American Dream TV as Central Florida Host
- Tickeron Unveils AI-Powered Trading Insights Aligned with Key Monthly Consumer Data
- 360Massage Launches Custom-Built Massage Chairs Designed to Match Modern Homes
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
- City of Naperville Launches New and Improved eBill Portal
- Artificial Intelligence Leader Releases Children's Book on Veterans Day
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- Holiday Pond Lighting Ideas for Chicago-Area Water Features
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil